You are here

Article Text

Article menu
Download PDFPDF
Research Article
Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.
  1. F Van Gerwen,
  2. J K Van der Korst,
  3. F W Gribnau

    Abstract

    In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred twice as often under phenylbutazone as under naproxen.

    https://doi.org/10.1136/ard.37.1.85

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.